Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01250938
Other study ID # 1108011843
Secondary ID Autism Speaks 57
Status Completed
Phase N/A
First received
Last updated
Start date July 2009
Est. completion date May 2019

Study information

Verified date May 2023
Source University of California, Los Angeles
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to test the applicability of a caregiver-implemented autism intervention protocol to a deliberately recruited low-income, underserved population.


Description:

Families of racial/ethnic minority, lower levels of education, and those who live in non-metropolitan areas have been found to experience greater limitations in accessing services for Autism Spectrum Disorder (ASD) (Thomas, Ellis, McLaurin, Daniels, & Morrissey, 2007). Black and Hispanic children have been found to have lower odds of having a documented ASD classification than white children (Mandell, Wiggins, Arnstein Carpenter, Daniels, Durkin et al., 2009) and of those children who do receive an ASD diagnosis, many of them are not diagnosed in early childhood. The age of first ASD diagnosis received has been found to be significantly higher for African American and Latino children compared to white children (Mandell, Listerud, Levy, & Pinto-Martin, 2002). For these reasons, it is important that the effectiveness of intensive early intervention for children with ASD is examined across varying cultural and socioeconomic backgrounds. This project is directed by Dr. Catherine Lord at the University of Michigan, in collaboration with Dr. Amy Wetherby at Florida State University to test the applicability of a modified caregiver-implemented autism intervention (Modified Early Social Interaction; ESI) to a deliberately recruited low-income, underserved population. UM will recruit 28 children and FSU will recruit 16 children diagnosed with ASD who are between 24 and 42 months of age over a period of 3 years, totaling 44 caregiver-child dyads. This study will utilize a multiple baseline single-subject research design. Dyads will complete 1 month of weekly 1-hour baseline observations followed by three months of the modified ESI intervention. Child and family characteristics predicting response to intervention will be identified and findings will contribute to the development of autism interventions serving families from diverse backgrounds.


Recruitment information / eligibility

Status Completed
Enrollment 44
Est. completion date May 2019
Est. primary completion date May 2019
Accepts healthy volunteers No
Gender All
Age group 24 Months to 54 Months
Eligibility Inclusion Criteria: - caregiver(s) with less than a 4-year college degree - family income equal to or below 2x the federal poverty line - English as the predominantly-spoken language. - child received diagnosis of autism spectrum disorder before treatment - child is between 24 and 42 months at the start of treatment - child has normal hearing and adequate motor control to make simple actions (giving, reaching) - family agrees to 2-4 weeks of weekly 1-hour observations, 3 months of 2 intervention sessions per week, and 3 months of 1 intervention session per month. - family agrees to pre-treatment, post-treatment, and follow-up evaluation and videotaping of intervention sessions and weekly video check during the treatment. Exclusion Criteria: -Must meet eligibility requirements stated above.

Study Design


Intervention

Behavioral:
ESI - Community Outreach
This is an individualized caregiver-implemented intervention (ESI-CO) offered in 2 weekly sessions to teach caregivers how to embed strategies to support social communication skills within everyday routines, activities, and places for 3 months. Additionally, families receive 6 months (3 months during weekly home sessions and three months upon the completion of weekly home sessions) of resource support to identify local and community autism programs available for continued intervention and services.

Locations

Country Name City State
United States Florida State University Tallahassee Florida
United States Weill Cornell Medical College White Plains New York

Sponsors (4)

Lead Sponsor Collaborator
University of California, Los Angeles Autism Speaks, Florida State University, National Institute of Mental Health (NIMH)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Caregiver Transactional Support Measures caregiver's development of behavioral strategies to support child's social and communicative behavior. Weekly
Secondary Child Outcome Child measures of autism symptoms, social communication, developmental level, and adaptive behavior. All measures pre-treatment, post-treatment, and at 3 month follow-up. Some measures weekly and monthly
Secondary Caregiver Outcome Caregiver measures self-reported family functioning, resources, well-being and treatment adherence, fidelity, and satisfaction All measures pre-treatment, post-treatment, and at 3 month follow-up. Some measures weekly and monthly
See also
  Status Clinical Trial Phase
Active, not recruiting NCT02625116 - ELENA Cohort: A Long-term Longitudinal Study in a Pediatric Sample With Autism Spectrum Disorders
Not yet recruiting NCT06381856 - Improving Participation of Autistic Children and Adolescents in the Habilitation Process
Recruiting NCT02280746 - Gluten for Autism Spectrum Disorders N/A
Completed NCT01945957 - Brain Imaging of Intranasal Oxytocin Treatment in Autism Phase 1
Completed NCT01661855 - A Pilot Study of Riluzole Versus Placebo in the Treatment of Children and Adolescents With ASD Phase 2
Completed NCT01592747 - Withdrawal Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified Previously Treated With Memantine Phase 2
Completed NCT01780090 - Handheld Technology for Speech Development in Students With Autism N/A
Completed NCT01691066 - Pivotal Response Treatment for Infants At-Risk for Autism Spectrum Disorder N/A
Completed NCT01694667 - Omega-3 Fatty Acids for Hyperactivity Treatment in Autism Spectrum Disorder Phase 2
Active, not recruiting NCT01417026 - Intranasal Oxytocin and Learning in Autism Phase 2
Enrolling by invitation NCT01364818 - Brain Connectivity in Neurodevelopmental Disorders in Response to Treatment N/A
Completed NCT01695200 - Omega-3 Fatty Acids in Autism Spectrum Disorders Phase 4
Completed NCT02300597 - Internet-based Support for Young People With ADHD and Autism - a Controlled Study N/A
Not yet recruiting NCT00695812 - The Development of Younger Siblings of Children With Autism Now at 10 Years of Age N/A
Completed NCT01675414 - Understanding Gastrointestinal Conditions in Children With Autism Spectrum Disorder (ASD) N/A
Recruiting NCT05910502 - Project AFECT (Autism Family Empowerment Coaching and Training Program) N/A
Completed NCT02081027 - Pilot Study of Riluzole for Drug-Refractory Irritability in Autism Spectrum Disorders Early Phase 1
Completed NCT02797379 - The Development of a Psychoeducational Tool to Manage Anxiety in People With Autism Spectrum Disorders N/A
Terminated NCT01730079 - Near Infrared Spectroscopy in Children With Autism and ADHD
Completed NCT01603225 - Transcranial Direct Current Stimulation and Autism